Mufg Securities Americas Inc. Acquires 2,601 Shares of Amgen Inc. $AMGN

Mufg Securities Americas Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 21.8% during the 3rd quarter, Holdings Channel reports. The firm owned 14,518 shares of the medical research company’s stock after acquiring an additional 2,601 shares during the period. Mufg Securities Americas Inc.’s holdings in Amgen were worth $4,097,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in AMGN. Vanguard Group Inc. boosted its holdings in Amgen by 0.3% during the third quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after buying an additional 165,281 shares during the last quarter. State Street Corp raised its position in shares of Amgen by 0.6% in the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after acquiring an additional 177,035 shares during the period. Geode Capital Management LLC boosted its stake in Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after acquiring an additional 291,271 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after purchasing an additional 687,735 shares during the period. Finally, Laurel Wealth Advisors LLC increased its stake in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 1.2%

NASDAQ:AMGN opened at $379.42 on Tuesday. The stock has a 50-day simple moving average of $344.29 and a 200 day simple moving average of $317.21. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12. The company has a market cap of $204.53 billion, a PE ratio of 26.66, a PEG ratio of 3.71 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. Argus lifted their price target on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Daiwa Securities Group raised their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Rothschild & Co Redburn lifted their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Wells Fargo & Company increased their price target on Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Leerink Partners boosted their price objective on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $351.76.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.